ZBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zenas Biopharma Inc (ZBIO) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks clear positive momentum in its technical indicators, and while there is potential for long-term growth based on its drug pipeline, the current market sentiment and financial performance suggest waiting for more clarity or a better entry point.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 29.126, leaning towards oversold but not providing a clear signal. The stock is trading near its support level (S2: 23.505), but no strong reversal signals are present. Moving averages are converging, showing no clear trend.
Analysts like Wedbush highlight a clinically de-risked drug pipeline with potential FDA approval, which could drive long-term growth. The company's drug obexelimab has an 80% likelihood of approval for IgG4-RD, according to Citi.
Morgan Stanley downgraded the stock due to weaker-than-expected Phase 3 results for obexelimab, which may limit its market share. The stock is down 2.73% in regular trading, and technical indicators show bearish momentum.
In Q3 2025, the company reported no revenue growth and a net income loss of $51.5M, though the loss improved by 33.4% YoY. EPS also improved by 32.61% YoY but remains negative at -1.22. The company is not yet profitable.
Analysts are mixed: Wedbush rates the stock as Outperform, citing long-term growth potential. Citi maintains a Buy rating but lowered the price target to $43, citing weaker trial results. Morgan Stanley downgraded the stock to Equal Weight with a $19 target due to lower-than-expected efficacy in clinical trials.
